摘要
Abstract
Objective To observe the therapeutic effects of 48 -week telbivudine treatment in patients with cirrhosis caused by hepatitis B vims(HBV). Methods In this cohort study, 93 patients with liver cirrhosis caused by HBV were divided into three groups randomly: telbivudine (LDT) group ( n = 32), lamivudine ( LMV ) group ( n = 31 ), and control group ( n = 30): conventional liver protection treatment. The course of treatment lasted 48 weeks. The virological and biochemical parameters, PT, hepatic fibrosis index and Child -Pugh score were observed at different time points during treatment. Results The HBV DNA levels in telbivudine group were significantly decreased. The negative rates of HBV DNA ( ＜500 copies/ml) were correspondingly and significantly higher than those in lamivudine group and control group (P ＜0.05). At week 24 and 48, the negative rates of hepatitis B e antigen(HBeAg) and the rates of HBeAg/anti - HBe sero -conversion in telbivudine group were significantly higher than those in control group(P ＜0.01 ). ALT, AST, total bilirubin, hepatic fibrosis index and Child - Pngh score were significantly improved in telbivudine group and lamivudine group after treatment ( P ＜0.05). Conclusion Telbivudine can rapidly and effectively inhibit HBV DNA replication and improve liver function, hepatic fibrosis index and Child -Pngh score in patients with liver cirrhosis caused by HBV.关键词
肝炎,乙型,慢性/肝硬化/拉米夫定/替比夫定Key words
hepatitis B, chronic/ liver cirrhosis/ lamivudine/ telbivudine分类
医药卫生
